Adhera Therapeutics, Inc.
ATRX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -1.85 | 0.79 | 0.89 |
| FCF Yield | -74.77% | -0.18% | -0.33% | -3.36% |
| EV / EBITDA | 0.00 | 0.00 | -93.81 | -23.63 |
| Quality | ||||
| ROIC | 11.90% | 3.65% | 24.09% | 248.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -62.30% |
| Cash Conversion Ratio | 0.67 | 0.10 | 0.16 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | – |
| Free Cash Flow Growth | -112.78% | -13.10% | 93.27% | 9.79% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -3.17 | -0.47 |
| Interest Coverage | -0.51 | -0.47 | -1.15 | -17.09 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -1,252.07 |